Publisher Full Text
COVID-19: consider cytokine storm syndromes and immunosuppression.Lancet. 2020 03 28; 395(10229):1033-1034.Lct
Links
MeSH
Pub Type(s)
Letter
Language
eng
PubMed ID
32192578
Clinical Trial Links
The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.
Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy
Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19
Clinical Characteristics and Outcomes of 187 Critically Ill Patients With Coronavirus Disease 2019 (COVID-19)
Citation
Mehta, Puja, et al. "COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression." Lancet (London, England), vol. 395, no. 10229, 2020, pp. 1033-1034.
Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England), 395(10229), 1033-1034. https://doi.org/10.1016/S0140-6736(20)30628-0
Mehta P, et al. COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression. Lancet. 2020 03 28;395(10229):1033-1034. PubMed PMID: 32192578.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - COVID-19: consider cytokine storm syndromes and immunosuppression.
AU - Mehta,Puja,
AU - McAuley,Daniel F,
AU - Brown,Michael,
AU - Sanchez,Emilie,
AU - Tattersall,Rachel S,
AU - Manson,Jessica J,
AU - ,,
Y1 - 2020/03/16/
PY - 2020/03/08/received
PY - 2020/03/11/accepted
PY - 2020/3/21/pubmed
PY - 2020/4/4/medline
PY - 2020/3/21/entrez
SP - 1033
EP - 1034
JF - Lancet (London, England)
JO - Lancet
VL - 395
IS - 10229
SN - 1474-547X
UR - https://www.unboundmedicine.com/medline/citation/32192578/full_citation
L2 - https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(20)30628-0
DB - PRIME
DP - Unbound Medicine
ER -